211 related articles for article (PubMed ID: 31125088)
1. Surgery, Octreotide, Temozolomide, Bevacizumab, Radiotherapy, and Pegvisomant Treatment of an AIP Mutation‒Positive Child.
Dutta P; Reddy KS; Rai A; Madugundu AK; Solanki HS; Bhansali A; Radotra BD; Kumar N; Collier D; Iacovazzo D; Gupta P; Raja R; Gowda H; Pandey A; Devgun JS; Korbonits M
J Clin Endocrinol Metab; 2019 Aug; 104(8):3539-3544. PubMed ID: 31125088
[TBL] [Abstract][Full Text] [Related]
2. Resistant Paediatric Somatotropinomas due to AIP Mutations: Role of Pegvisomant.
Joshi K; Daly AF; Beckers A; Zacharin M
Horm Res Paediatr; 2018; 90(3):196-202. PubMed ID: 29953972
[TBL] [Abstract][Full Text] [Related]
3. Large-scale second-hit AIP deletion causing a pediatric growth hormone-secreting pituitary adenoma: Case report and review of literature.
Gummadavelli A; Dinauer C; McGuone D; Vining EM; Erson-Omay EZ; Omay SB
J Clin Neurosci; 2020 Aug; 78():420-422. PubMed ID: 32336638
[TBL] [Abstract][Full Text] [Related]
4. Combined treatment with octreotide LAR and pegvisomant in patients with pituitary gigantism: clinical evaluation and genetic screening.
Mangupli R; Rostomyan L; Castermans E; Caberg JH; Camperos P; Krivoy J; Cuauro E; Bours V; Daly AF; Beckers A
Pituitary; 2016 Oct; 19(5):507-14. PubMed ID: 27287035
[TBL] [Abstract][Full Text] [Related]
5. Aggressive prolactinoma in a child related to germline mutation in the ARYL hydrocarbon receptor interacting protein (AIP) gene.
Naves LA; Jaffrain-Rea ML; Vêncio SA; Jacomini CZ; Casulari LA; Daly AF; Beckers A
Arq Bras Endocrinol Metabol; 2010 Nov; 54(8):761-7. PubMed ID: 21340166
[TBL] [Abstract][Full Text] [Related]
6. Aryl hydrocarbon receptor interacting protein (AIP) gene mutation analysis in children and adolescents with sporadic pituitary adenomas.
Georgitsi M; De Menis E; Cannavò S; Mäkinen MJ; Tuppurainen K; Pauletto P; Curtò L; Weil RJ; Paschke R; Zielinski G; Wasik A; Lubinski J; Vahteristo P; Karhu A; Aaltonen LA
Clin Endocrinol (Oxf); 2008 Oct; 69(4):621-7. PubMed ID: 18410548
[TBL] [Abstract][Full Text] [Related]
7. Significant Benefits of AIP Testing and Clinical Screening in Familial Isolated and Young-onset Pituitary Tumors.
Marques P; Caimari F; Hernández-Ramírez LC; Collier D; Iacovazzo D; Ronaldson A; Magid K; Lim CT; Stals K; Ellard S; Grossman AB; Korbonits M;
J Clin Endocrinol Metab; 2020 Jun; 105(6):e2247-60. PubMed ID: 31996917
[TBL] [Abstract][Full Text] [Related]
8. miR-34a is upregulated in AIP-mutated somatotropinomas and promotes octreotide resistance.
Bogner EM; Daly AF; Gulde S; Karhu A; Irmler M; Beckers J; Mohr H; Beckers A; Pellegata NS
Int J Cancer; 2020 Dec; 147(12):3523-3538. PubMed ID: 32856736
[TBL] [Abstract][Full Text] [Related]
9. [Recent trends in the pathophysiology and treatment of pituitary adenomas].
Matsuno A
Brain Nerve; 2009 Aug; 61(8):957-62. PubMed ID: 19697885
[TBL] [Abstract][Full Text] [Related]
10. A novel truncating AIP mutation, p.W279*, in a familial isolated pituitary adenoma (FIPA) kindred.
Cansu GB; Taşkıran B; Trivellin G; Faucz FR; Stratakis CA
Hormones (Athens); 2016 Jul; 15(3):441-444. PubMed ID: 27838609
[TBL] [Abstract][Full Text] [Related]
11. Impact of preoperative pasireotide therapy on invasive octreotide-resistant acromegaly.
Yamamoto R; Robert Shima K; Igawa H; Kaikoi Y; Sasagawa Y; Hayashi Y; Inoshita N; Fukuoka H; Takahashi Y; Takamura T
Endocr J; 2018 Oct; 65(10):1061-1067. PubMed ID: 30078825
[TBL] [Abstract][Full Text] [Related]
12. Aggressive pituitary adenomas occurring in young patients in a large Polynesian kindred with a germline R271W mutation in the AIP gene.
Jennings JE; Georgitsi M; Holdaway I; Daly AF; Tichomirowa M; Beckers A; Aaltonen LA; Karhu A; Cameron FJ
Eur J Endocrinol; 2009 Nov; 161(5):799-804. PubMed ID: 19684062
[TBL] [Abstract][Full Text] [Related]
13. Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients.
Cazabat L; Bouligand J; Salenave S; Bernier M; Gaillard S; Parker F; Young J; Guiochon-Mantel A; Chanson P
J Clin Endocrinol Metab; 2012 Apr; 97(4):E663-70. PubMed ID: 22319033
[TBL] [Abstract][Full Text] [Related]
14. Eight-year follow-up of a child with a GH/prolactin-secreting adenoma: efficacy of pegvisomant therapy.
Bergamaschi S; Ronchi CL; Giavoli C; Ferrante E; Verrua E; Ferrari DI; Lania A; Rusconi R; Spada A; Beck-Peccoz P
Horm Res Paediatr; 2010; 73(1):74-9. PubMed ID: 20190543
[TBL] [Abstract][Full Text] [Related]
15. Sporadic and genetic forms of paediatric somatotropinoma: a retrospective analysis of seven cases and a review of the literature.
Nozières C; Berlier P; Dupuis C; Raynaud-Ravni C; Morel Y; Chazot FB; Nicolino M
Orphanet J Rare Dis; 2011 Oct; 6():67. PubMed ID: 22024364
[TBL] [Abstract][Full Text] [Related]
16. Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly.
Morin E; Berthelet F; Weisnagel J; Bidlingmaier M; Serri O
Pituitary; 2012 Mar; 15(1):97-100. PubMed ID: 20407837
[TBL] [Abstract][Full Text] [Related]
17. Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptor-interacting protein gene.
Naves LA; Daly AF; Vanbellinghen JF; Casulari LA; Spilioti C; Magalhães AV; Azevedo MF; Giacomini LA; Nascimento PP; Nunes RO; Rosa JW; Jaffrain-Rea ML; Bours V; Beckers A
Eur J Endocrinol; 2007 Oct; 157(4):383-91. PubMed ID: 17893251
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and treatment of pituitary adenomas.
Chanson P; Salenave S
Minerva Endocrinol; 2004 Dec; 29(4):241-75. PubMed ID: 15765032
[TBL] [Abstract][Full Text] [Related]
19. Clinical features and treatment of pediatric somatotropinoma: case study of an aggressive tumor due to a new AIP mutation and extensive literature review.
Personnier C; Cazabat L; Bertherat J; Gaillard S; Souberbielle JC; Habrand JL; Dufour C; Clauser E; SainteRose C; Polak M
Horm Res Paediatr; 2011; 75(6):392-402. PubMed ID: 21546764
[TBL] [Abstract][Full Text] [Related]
20. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families.
Daly AF; Vanbellinghen JF; Khoo SK; Jaffrain-Rea ML; Naves LA; Guitelman MA; Murat A; Emy P; Gimenez-Roqueplo AP; Tamburrano G; Raverot G; Barlier A; De Herder W; Penfornis A; Ciccarelli E; Estour B; Lecomte P; Gatta B; Chabre O; Sabaté MI; Bertagna X; Garcia Basavilbaso N; Stalldecker G; Colao A; Ferolla P; Wémeau JL; Caron P; Sadoul JL; Oneto A; Archambeaud F; Calender A; Sinilnikova O; Montañana CF; Cavagnini F; Hana V; Solano A; Delettieres D; Luccio-Camelo DC; Basso A; Rohmer V; Brue T; Bours V; Teh BT; Beckers A
J Clin Endocrinol Metab; 2007 May; 92(5):1891-6. PubMed ID: 17244780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
